Nkarta Reports Positive Phase 1 Data
Apr 25, 2022 By MarketDepth
Nkarta, Inc. (Nasdaq: NKTX) today announced positive preliminary dose finding data for two lead engineered natural killer cell programs.
Shares of Nkarta, Inc. (Nasdaq: NKTX) surged over 86% in premarket trading following the announcement.
The company also stated that updated Phase 1 data from its independent dose finding studies of its two lead chimeric antigen receptor (CAR) natural killer (NK) cell therapy candidates, NKX101 and NKX019, in two distinct groups of hematologic malignancies will be submitted for presentation at a future medical meeting.
“We’re excited to see our CAR NK co-lead candidates, NKX101 and NKX019, show such striking early single-agent activity in heavily pretreated patient populations, with an exceptional safety profile without the side effects associated with CAR T cell therapies.These encouraging data across multiple indications further validate Nkarta’s best-in-class NK cell platform, as we seek to transform cancer treatment by bringing together the safety advantages of NK cells with an off-the-shelf modality designed to make the benefits of cell therapy accessible in a community setting.”Paul J. Hastings, President and CEO of Nkarta
Furthermore, the company continues to enroll patients in three-dose regimens of 1.5 billion NK cells per dose in the dose finding portions of the NKX101 and NKX019 trials.